Genprex Granted Chinese Patent For REQORSA Immunogene Therapy In Combination With PD-1 Antibodies To Treat Cancers
Portfolio Pulse from Benzinga Newsdesk
Genprex has been granted a Chinese patent for its REQORSA immunogene therapy in combination with PD-1 antibodies for cancer treatment. This expands the company's intellectual property rights and potentially opens up a new market for its product.
July 05, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of a Chinese patent for Genprex's REQORSA immunogene therapy could potentially open up a new market for the company, which may positively impact its stock in the short term.
The granting of a patent in China for Genprex's REQORSA immunogene therapy expands the company's intellectual property rights and potentially opens up a new market for its product. This could lead to increased revenues in the future, which is generally a positive signal for investors and could lead to a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100